Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 265

1.

Comparative Effectiveness Research in Inflammatory Bowel Disease: The VARSITY Study and Beyond.

Sands BE.

Gastroenterol Hepatol (N Y). 2019 Dec;15(12):682-684. No abstract available.

2.

Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. Reply.

Sands BE, Schreiber S, Lirio RA.

N Engl J Med. 2020 Jan 2;382(1):93-94. doi: 10.1056/NEJMc1915739. No abstract available.

PMID:
31875508
3.

Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. Reply.

Sands BE, Marano C.

N Engl J Med. 2020 Jan 2;382(1):91. doi: 10.1056/NEJMc1915042. No abstract available.

PMID:
31875505
4.

A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease.

Dulai PS, Amiot A, Peyrin-Biroulet L, Jairath V, Serrero M, Filippi J, Singh S, Pariente B, Loftus EV Jr, Roblin X, Kane S, Buisson A, Siegel CA, Bouhnik Y, Sandborn WJ, Lasch K, Rosario M, Feagan BG, Bojic D, Trang-Poisson C, Shen B, Altwegg R, Sands BE, Colombel JF, Carbonnel F; GETAID OBSERV-IBD, VICTORY Cohorts Collaboration*.

Aliment Pharmacol Ther. 2019 Dec 22. doi: 10.1111/apt.15609. [Epub ahead of print]

PMID:
31867766
5.

Mongersen (GED-0301) for Active Crohn's Disease: Results of a Phase 3 Study.

Sands BE, Feagan BG, Sandborn WJ, Schreiber S, Peyrin-Biroulet L, Frédéric Colombel J, Rossiter G, Usiskin K, Ather S, Zhan X, DʼHaens G.

Am J Gastroenterol. 2019 Dec 16. doi: 10.14309/ajg.0000000000000493. [Epub ahead of print]

PMID:
31850931
6.

Chaperone biomarkers of lifespan and penetrance track the dosages of many other proteins.

Burnaevskiy N, Sands B, Yun S, Tedesco PM, Johnson TE, Kaeberlein M, Brent R, Mendenhall A.

Nat Commun. 2019 Dec 16;10(1):5725. doi: 10.1038/s41467-019-13664-7.

7.

Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis: Ustekinumab PK and exposure-response in UC.

Adedokun OJ, Xu Z, Marano C, O'Brien C, Szapary P, Zhang H, Johanns J, Leong RW, Hisamatsu T, van Assche G, Danese S, Abreu MT, Sands BE, Sandborn WJ.

Clin Gastroenterol Hepatol. 2019 Dec 6. pii: S1542-3565(19)31403-X. doi: 10.1016/j.cgh.2019.11.059. [Epub ahead of print]

8.

Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open.

Sands BE, Armuzzi A, Marshall JK, Lindsay JO, Sandborn WJ, Danese S, Panés J, Bressler B, Colombel JF, Lawendy N, Maller E, Zhang H, Chan G, Salese L, Tsilkos K, Marren A, Su C.

Aliment Pharmacol Ther. 2020 Jan;51(2):271-280. doi: 10.1111/apt.15555. Epub 2019 Oct 29.

PMID:
31660640
9.

Anastomotic Ulcers After Ileocolic Resection for Crohn's Disease Are Common and Predict Recurrence.

Hirten RP, Ungaro RC, Castaneda D, Lopatin S, Sands BE, Colombel JF, Cohen BL.

Inflamm Bowel Dis. 2019 Oct 19. pii: izz224. doi: 10.1093/ibd/izz224. [Epub ahead of print]

PMID:
31639193
10.

Reply to Letter to the Editor of Dr. Lai and Colleagues.

Shmidt E, Saha S, Sands BE.

Inflamm Bowel Dis. 2019 Nov 14;25(12):e166. doi: 10.1093/ibd/izz238. No abstract available.

PMID:
31622457
11.

Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme.

Sandborn WJ, Panés J, Sands BE, Reinisch W, Su C, Lawendy N, Koram N, Fan H, Jones TV, Modesto I, Quirk D, Danese S.

Aliment Pharmacol Ther. 2019 Nov;50(10):1068-1076. doi: 10.1111/apt.15514. Epub 2019 Oct 9.

12.

Reproductive sublethal effects of macrocyclic lactones and synthetic pyrethroids on the dung beetle Onthophagus similis.

Weaving H, Sands B, Wall R.

Bull Entomol Res. 2019 Oct 1:1-6. doi: 10.1017/S0007485319000567. [Epub ahead of print]

PMID:
31571556
13.

Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.

Sands BE, Peyrin-Biroulet L, Loftus EV Jr, Danese S, Colombel JF, Törüner M, Jonaitis L, Abhyankar B, Chen J, Rogers R, Lirio RA, Bornstein JD, Schreiber S; VARSITY Study Group.

N Engl J Med. 2019 Sep 26;381(13):1215-1226. doi: 10.1056/NEJMoa1905725.

PMID:
31553834
14.

Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.

Sands BE, Sandborn WJ, Panaccione R, O'Brien CD, Zhang H, Johanns J, Adedokun OJ, Li K, Peyrin-Biroulet L, Van Assche G, Danese S, Targan S, Abreu MT, Hisamatsu T, Szapary P, Marano C; UNIFI Study Group.

N Engl J Med. 2019 Sep 26;381(13):1201-1214. doi: 10.1056/NEJMoa1900750.

PMID:
31553833
15.

Efficient augmentation and relaxation learning for individualized treatment rules using observational data.

Zhao YQ, Laber EB, Ning Y, Saha S, Sands BE.

J Mach Learn Res. 2019;20. pii: 48.

16.

Comparison of the EMA and FDA Guidelines on Ulcerative Colitis Drug Development.

Reinisch W, Gottlieb K, Colombel JF, Danese S, Panaccione R, Panes J, Peyrin-Biroulet L, Rubin D, Sands BE, Schreiber S, Vermeire S, Mulberg A, Sandborn B.

Clin Gastroenterol Hepatol. 2019 Aug;17(9):1673-1679.e1. doi: 10.1016/j.cgh.2018.10.032. Epub 2018 Oct 26. Review.

PMID:
31352970
17.

In vivo measurements reveal a single 5'-intron is sufficient to increase protein expression level in Caenorhabditis elegans.

Crane MM, Sands B, Battaglia C, Johnson B, Yun S, Kaeberlein M, Brent R, Mendenhall A.

Sci Rep. 2019 Jun 24;9(1):9192. doi: 10.1038/s41598-019-45517-0.

18.

Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases.

Dulai PS, Peyrin-Biroulet L, Danese S, Sands BE, Dignass A, Turner D, Mantzaris G, Schölmerich J, Mary JY, Reinisch W, Sandborn WJ.

Gastroenterology. 2019 Oct;157(4):1032-1043.e1. doi: 10.1053/j.gastro.2019.06.018. Epub 2019 Jun 19. Review.

PMID:
31228441
19.

IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease.

Hanauer SB, Sandborn WJ, Feagan BG, Gasink C, Jacobstein D, Zou B, Johanns J, Adedokun OJ, Sands BE, Rutgeerts P, de Villiers WJS, Colombel JF, Ghosh S.

J Crohns Colitis. 2020 Jan 1;14(1):23-32. doi: 10.1093/ecco-jcc/jjz110.

PMID:
31158271
20.

Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative Colitis.

Sands BE, Taub PR, Armuzzi A, Friedman GS, Moscariello M, Lawendy N, Pedersen RD, Chan G, Nduaka CI, Quirk D, Salese L, Su C, Feagan BG.

Clin Gastroenterol Hepatol. 2020 Jan;18(1):123-132.e3. doi: 10.1016/j.cgh.2019.04.059. Epub 2019 May 8.

21.

Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes.

Koliani-Pace JL, Singh S, Luo M, Hirten R, Aniwan S, Kochhar G, Chang S, Lukin D, Gao Y, Bohm M, Swaminath A, Gupta N, Shmidt E, Meserve J, Winters A, Chablaney S, Faleck DM, Yang J, Huang Z, Boland BS, Shashi P, Weiss A, Hudesman D, Varma S, Fischer M, Sultan K, Shen B, Kane S, Loftus EV, Sands BE, Colombel JF, Sandborn WJ, Lasch K, Siegel CA, Dulai PS.

Inflamm Bowel Dis. 2019 Oct 18;25(11):1854-1861. doi: 10.1093/ibd/izz071.

22.

Novel Non-biologic Targets for Inflammatory Bowel Disease.

Shukla T, Sands BE.

Curr Gastroenterol Rep. 2019 Apr 23;21(5):22. doi: 10.1007/s11894-019-0689-2. Review.

PMID:
31016396
23.

Response to Chapman and Jones.

Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Sands BE.

Am J Gastroenterol. 2019 May;114(5):828. doi: 10.14309/ajg.0000000000000217. No abstract available.

PMID:
30985301
24.

Response to Ribaldone.

Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Sands BE.

Am J Gastroenterol. 2019 May;114(5):826-827. doi: 10.14309/ajg.0000000000000216. No abstract available.

PMID:
30985300
25.

Presenting symptoms in inflammatory bowel disease: descriptive analysis of a community-based inception cohort.

Perler B, Ungaro R, Baird G, Mallette M, Bright R, Shah S, Shapiro J, Sands BE.

BMC Gastroenterol. 2019 Apr 2;19(1):47. doi: 10.1186/s12876-019-0963-7.

26.

The Impact of Raising the Bar for Clinical Trials in Ulcerative Colitis.

Sands BE, Cheifetz AS, Nduaka CI, Quirk D, Wang W, Maller E, Friedman GS, Su C, Higgins PDR.

J Crohns Colitis. 2019 Sep 19;13(9):1217-1226. doi: 10.1093/ecco-jcc/jjz038.

27.

Erectile Dysfunction Is Highly Prevalent in Men With Newly Diagnosed Inflammatory Bowel Disease.

Shmidt E, Suárez-Fariñas M, Mallette M, Moniz H, Bright R, Shah SA, Merrick M, Shapiro J, Xu F, Saha S, Sands BE.

Inflamm Bowel Dis. 2019 Jul 17;25(8):1408-1416. doi: 10.1093/ibd/izy401.

PMID:
30861068
28.

Microbial Engraftment and Efficacy of Fecal Microbiota Transplant for Clostridium Difficile in Patients With and Without Inflammatory Bowel Disease.

Hirten RP, Grinspan A, Fu SC, Luo Y, Suarez-Farinas M, Rowland J, Contijoch EJ, Mogno I, Yang N, Luong T, Labrias PR, Peter I, Cho JH, Sands BE, Colombel JF, Faith JJ, Clemente JC.

Inflamm Bowel Dis. 2019 May 4;25(6):969-979. doi: 10.1093/ibd/izy398.

PMID:
30852592
29.

A Longitudinal Study of Sexual Function in Women With Newly Diagnosed Inflammatory Bowel Disease.

Shmidt E, Suárez-Fariñas M, Mallette M, Moniz H, Bright R, Shah SA, Merrick M, Shapiro J, Xu F, Sands B, Saha S.

Inflamm Bowel Dis. 2019 Jun 18;25(7):1262-1270. doi: 10.1093/ibd/izy397.

PMID:
30726913
30.

Gut microbiota density influences host physiology and is shaped by host and microbial factors.

Contijoch EJ, Britton GJ, Yang C, Mogno I, Li Z, Ng R, Llewellyn SR, Hira S, Johnson C, Rabinowitz KM, Barkan R, Dotan I, Hirten RP, Fu SC, Luo Y, Yang N, Luong T, Labrias PR, Lira S, Peter I, Grinspan A, Clemente JC, Kosoy R, Kim-Schulze S, Qin X, Castillo A, Hurley A, Atreja A, Rogers J, Fasihuddin F, Saliaj M, Nolan A, Reyes-Mercedes P, Rodriguez C, Aly S, Santa-Cruz K, Peters L, Suárez-Fariñas M, Huang R, Hao K, Zhu J, Zhang B, Losic B, Irizar H, Song WM, Di Narzo A, Wang W, Cohen BL, DiMaio C, Greenwald D, Itzkowitz S, Lucas A, Marion J, Maser E, Ungaro R, Naymagon S, Novak J, Shah B, Ullman T, Rubin P, George J, Legnani P, Telesco SE, Friedman JR, Brodmerkel C, Plevy S, Cho JH, Colombel JF, Schadt EE, Argmann C, Dubinsky M, Kasarskis A, Sands B, Faith JJ.

Elife. 2019 Jan 22;8. pii: e40553. doi: 10.7554/eLife.40553.

31.

Microbiotas from Humans with Inflammatory Bowel Disease Alter the Balance of Gut Th17 and RORγt+ Regulatory T Cells and Exacerbate Colitis in Mice.

Britton GJ, Contijoch EJ, Mogno I, Vennaro OH, Llewellyn SR, Ng R, Li Z, Mortha A, Merad M, Das A, Gevers D, McGovern DPB, Singh N, Braun J, Jacobs JP, Clemente JC, Grinspan A, Sands BE, Colombel JF, Dubinsky MC, Faith JJ.

Immunity. 2019 Jan 15;50(1):212-224.e4. doi: 10.1016/j.immuni.2018.12.015.

32.

Response to Chamberlin and Borody.

Lichtenstein GR, Loftus EV Jr, Isaacs KL, Regueiro MD, Sands BE.

Am J Gastroenterol. 2019 Jan;114(1):171-174. doi: 10.14309/ajg.0000000000000077. No abstract available.

PMID:
30633034
33.

Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis.

Faleck DM, Winters A, Chablaney S, Shashi P, Meserve J, Weiss A, Aniwan S, Koliani-Pace JL, Kochhar G, Boland BS, Singh S, Hirten R, Shmidt E, Kesar V, Lasch K, Luo M, Bohm M, Varma S, Fischer M, Hudesman D, Chang S, Lukin D, Sultan K, Swaminath A, Gupta N, Siegel CA, Shen B, Sandborn WJ, Kane S, Loftus EV Jr, Sands BE, Colombel JF, Dulai PS, Ungaro R.

Clin Gastroenterol Hepatol. 2019 Nov;17(12):2497-2505.e1. doi: 10.1016/j.cgh.2018.12.040. Epub 2019 Jan 6.

34.

Vedolizumab in Combination With Corticosteroids for Induction Therapy in Crohn's Disease: A Post Hoc Analysis of GEMINI 2 and 3.

Sands BE, Van Assche G, Tudor D, Akhundova-Unadkat G, Curtis RI, Tan T.

Inflamm Bowel Dis. 2019 Jul 17;25(8):1375-1382. doi: 10.1093/ibd/izy384.

35.

Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials.

Sandborn WJ, Panés J, D'Haens GR, Sands BE, Su C, Moscariello M, Jones T, Pedersen R, Friedman GS, Lawendy N, Chan G.

Clin Gastroenterol Hepatol. 2019 Jul;17(8):1541-1550. doi: 10.1016/j.cgh.2018.11.035. Epub 2018 Nov 23.

36.

Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies.

Panés J, Vermeire S, Lindsay JO, Sands BE, Su C, Friedman G, Zhang H, Yarlas A, Bayliss M, Maher S, Cappelleri JC, Bushmakin AG, Rubin DT.

J Crohns Colitis. 2019 Jan 1;13(1):139-140. doi: 10.1093/ecco-jcc/jjy135. No abstract available.

37.

Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium.

Narula N, Peerani F, Meserve J, Kochhar G, Chaudrey K, Hartke J, Chilukuri P, Koliani-Pace J, Winters A, Katta L, Shmidt E, Hirten R, Faleck D, Parikh MP, Whitehead D, Boland BS, Singh S, Sagi SV, Fischer M, Chang S, Barocas M, Luo M, Lasch K, Bohm M, Lukin D, Sultan K, Swaminath A, Hudesman D, Gupta N, Shen B, Kane S, Loftus EV, Siegel CA, Sands BE, Colombel JF, Sandborn WJ, Dulai PS.

Am J Gastroenterol. 2018 Dec;113(12):696. doi: 10.1038/s41395-018-0401-4.

38.

Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1.

Reinisch W, Bressler B, Curtis R, Parikh A, Yang H, Rosario M, Røseth A, Danese S, Feagan B, Sands BE, Ginsburg P, Dassopoulos T, Lewis J, Xu J, Wyant T.

Inflamm Bowel Dis. 2019 Mar 14;25(4):803-810. doi: 10.1093/ibd/izy304.

39.

Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases.

Meserve J, Aniwan S, Koliani-Pace JL, Shashi P, Weiss A, Faleck D, Winters A, Chablaney S, Kochhar G, Boland BS, Singh S, Hirten R, Shmidt E, Hartke JG, Chilukuri P, Bohm M, Sagi SV, Fischer M, Lukin D, Hudesman D, Chang S, Gao Y, Sultan K, Swaminath A, Gupta N, Kane S, Loftus EV Jr, Shen B, Sands BE, Colombel JF, Siegel CA, Sandborn WJ, Dulai PS.

Clin Gastroenterol Hepatol. 2019 Jul;17(8):1533-1540.e2. doi: 10.1016/j.cgh.2018.09.035. Epub 2018 Sep 27.

40.

Methotrexate Is Not Superior to Placebo in Maintaining Steroid-Free Response or Remission in Ulcerative Colitis.

Herfarth H, Barnes EL, Valentine JF, Hanson J, Higgins PDR, Isaacs KL, Jackson S, Osterman MT, Anton K, Ivanova A, Long MD, Martin C, Sandler RS, Abraham B, Cross RK, Dryden G, Fischer M, Harlan W, Levy C, McCabe R, Polyak S, Saha S, Williams E, Yajnik V, Serrano J, Sands BE, Lewis JD; Clinical Research Alliance of the Crohn’s and Colitis Foundation.

Gastroenterology. 2018 Oct;155(4):1098-1108.e9. doi: 10.1053/j.gastro.2018.06.046. Epub 2018 Jun 30.

41.

Sex-Based Differences in Incidence of Inflammatory Bowel Diseases-Pooled Analysis of Population-Based Studies From Western Countries.

Shah SC, Khalili H, Gower-Rousseau C, Olen O, Benchimol EI, Lynge E, Nielsen KR, Brassard P, Vutcovici M, Bitton A, Bernstein CN, Leddin D, Tamim H, Stefansson T, Loftus EV Jr, Moum B, Tang W, Ng SC, Gearry R, Sincic B, Bell S, Sands BE, Lakatos PL, Végh Z, Ott C, Kaplan GG, Burisch J, Colombel JF.

Gastroenterology. 2018 Oct;155(4):1079-1089.e3. doi: 10.1053/j.gastro.2018.06.043. Epub 2018 Jun 27.

PMID:
29958857
42.

Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium.

Narula N, Peerani F, Meserve J, Kochhar G, Chaudrey K, Hartke J, Chilukuri P, Koliani-Pace J, Winters A, Katta L, Shmidt E, Hirten R, Faleck D, Parikh MP, Whitehead D, Boland BS, Singh S, Sagi SV, Fischer M, Chang S, Barocas M, Luo M, Lasch K, Bohm M, Lukin D, Sultan K, Swaminath A, Hudesman D, Gupta N, Shen B, Kane S, Loftus EV, Siegel CA, Sands BE, Colombel JF, Sandborn WJ, Dulai PS.

Am J Gastroenterol. 2018 Sep;113(9):1345. doi: 10.1038/s41395-018-0162-0. Epub 2018 Jun 27. Erratum in: Am J Gastroenterol. 2018 Dec;113(12):1912.

43.

Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study.

Sands BE, Sandborn WJ, Feagan BG, Lichtenstein GR, Zhang H, Strauss R, Szapary P, Johanns J, Panes J, Vermeire S, O'Brien CD, Yang Z, Bertelsen K, Marano C; Peficitinib-UC Study Group.

J Crohns Colitis. 2018 Nov 9;12(10):1158-1169. doi: 10.1093/ecco-jcc/jjy085.

PMID:
29917064
44.

Correction: ACG Clinical Guideline: Management of Crohn's Disease in Adults.

Lichtenstein GR, Loftus EV Jr, Isaacs KL, Regueiro MD, Gerson LB, Sands BE.

Am J Gastroenterol. 2018 Jul;113(7):1101. doi: 10.1038/s41395-018-0120-x.

PMID:
29895986
45.

Climate variability differentially impacts thermal fitness traits in three coprophagic beetle species.

Nyamukondiwa C, Chidawanyika F, Machekano H, Mutamiswa R, Sands B, Mgidiswa N, Wall R.

PLoS One. 2018 Jun 6;13(6):e0198610. doi: 10.1371/journal.pone.0198610. eCollection 2018.

46.

Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease.

Dulai PS, Boland BS, Singh S, Chaudrey K, Koliani-Pace JL, Kochhar G, Parikh MP, Shmidt E, Hartke J, Chilukuri P, Meserve J, Whitehead D, Hirten R, Winters AC, Katta LG, Peerani F, Narula N, Sultan K, Swaminath A, Bohm M, Lukin D, Hudesman D, Chang JT, Rivera-Nieves J, Jairath V, Zou GY, Feagan BG, Shen B, Siegel CA, Loftus EV Jr, Kane S, Sands BE, Colombel JF, Sandborn WJ, Lasch K, Cao C.

Gastroenterology. 2018 Sep;155(3):687-695.e10. doi: 10.1053/j.gastro.2018.05.039. Epub 2018 May 30.

47.

Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy.

Sandborn WJ, Rutgeerts P, Gasink C, Jacobstein D, Zou B, Johanns J, Sands BE, Hanauer SB, Targan S, Ghosh S, de Villiers WJS, Colombel JF, Feagan BG.

Aliment Pharmacol Ther. 2018 Jul;48(1):65-77. doi: 10.1111/apt.14794. Epub 2018 May 24.

48.

Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.

Shmidt E, Kochhar G, Hartke J, Chilukuri P, Meserve J, Chaudrey K, Koliani-Pace JL, Hirten R, Faleck D, Barocas M, Luo M, Lasch K, Boland BS, Singh S, Vande Casteele N, Sagi SV, Fischer M, Chang S, Bohm M, Lukin D, Sultan K, Swaminath A, Hudesman D, Gupta N, Kane S, Loftus EV Jr, Sandborn WJ, Siegel CA, Sands BE, Colombel JF, Shen B, Dulai PS.

Inflamm Bowel Dis. 2018 Oct 12;24(11):2461-2467. doi: 10.1093/ibd/izy171.

49.

The Effects of Ustekinumab on Health-related Quality of Life in Patients With Moderate to Severe Crohn's Disease.

Sands BE, Han C, Gasink C, Jacobstein D, Szapary P, Gao LL, Lang Y, Targan S, Sandborn WJ, Feagan BG.

J Crohns Colitis. 2018 Jul 30;12(8):883-895. doi: 10.1093/ecco-jcc/jjy055.

PMID:
29726939
50.

ACG Clinical Guideline: Management of Crohn's Disease in Adults.

Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE.

Am J Gastroenterol. 2018 Apr;113(4):481-517. doi: 10.1038/ajg.2018.27. Epub 2018 Mar 27. Erratum in: Am J Gastroenterol. 2018 Jul;113(7):1101.

PMID:
29610508

Supplemental Content

Support Center